Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | SLC25A20 | O43772 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.76 |
| ▸ | GMNN | O75496 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palmitoyl-Carnitine SCHEMBL115183 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL288673 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL19182624 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL8050598 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL288242 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL17164609 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL25373354 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL187668 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Octanoylcarnitine SCHEMBL2915508 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL188470 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1910 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| CN-119791058-B | Pain rheumatism heat syndrome subtype modeling method, biomarker group application and detection method | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2026-05-19 | — | — | CN | claimed |
| US-20260120870-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | INNOBATION BIO CO LTD (KR) | 2026-04-30 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260014232-A1 | Pharmaceutical Composition of GLP-1 and GIP Receptor Dual Agonist and Use Thereof | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-01-15 | — | — | US | claimed |
| US-12493041-B2 | Apparatus for diagnosing solid cancers and method for providing information on solid cancer diagnosis | INNOBATION BIO CO., LTD. (KR) | 2025-12-09 | — | — | US | claimed |
| EP-4651897-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | Syntis Bio, Inc. (US) | 2025-11-26 | — | — | EP | claimed |
| EP-4616198-A1 | A METHOD OF EARLY PREDICTION OF RISK OF PRE-TERM PRE-ECLAMPSIA IN SPECIFIC POPULATION COHORTS | Metabolomic Diagnostics Limited (IE) | 2025-09-17 | — | — | EP | claimed |
| US-20250262305-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | ARS PHARMACEUTICALS INC. | 2025-08-21 | — | — | US | claimed |
| WO-2001012155-A1 | COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2001-02-22 | — | — | WO | claimed |
| EP-0796841-B1 | Bis alkanoyl esters of carnitine having bactericidal, fungicidal and antiprotozoal activity | SIGMA TAU IND FARMACEUTI (IT) | 2000-05-31 | — | — | EP | claimed |
| EP-0215697-B1 | ACYLCARNITINES AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL COMPARTMENTS | MERCK & CO. INC. (US) | 1992-03-25 | — | — | EP | claimed |
| US-4963525-A | POLYPEPTIDES | MERCK & CO., INC. (US) | 1990-10-16 | — | — | US | claimed |
| EP-0162764-B1 | COMPOSITION AND METHOD FOR ENHANCING ABSORPTION OF DRUGS FROM GASTROINTESTINAL TRACT USING ACYLCARNITINES | MERCK & CO. INC. (US) | 1989-08-09 | — | — | EP | claimed |
| US-4847298-A | DOPA COMPOUNDS OR ANTIBIOTICS | MERCK & CO., INC. (US) | 1989-07-11 | — | — | US | claimed |
| US-4731360-A | Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments | MERCK & CO., INC. (US) | 1988-03-15 | — | — | US | claimed |
| EP-0215697-A2 | Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments | MERCK & CO. INC. (US) | 1987-03-25 | — | — | EP | claimed |
| EP-0162764-A1 | Composition and method for enhancing absorption of drugs from gastrointestinal tract using acylcarnitines | MERCK & CO. INC. (US) | 1985-11-27 | — | — | EP | claimed |
| US-4537772-A | Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines | MERCK & CO., INC. (US) | 1985-08-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | TNF, PYCARD, VAPA | MAPT 3359/4885MEN1 3247/4885KMT2A 3991/4885 |
| US-20250262305-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | ADRA2C, ADRA2A, ADRB2 | MAPT 1617/4885MEN1 385/4885KMT2A 3017/4885 |
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | SHBG, HSD11B2, HSD11B1 | MAPT 3536/4885MEN1 21/4885KMT2A 831/4885 |
| US-20260120870-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | KYNU, CPT2, CPT1A | MAPT 4480/4885MEN1 1628/4885KMT2A 564/4885 |
| US-20260014232-A1 | Pharmaceutical Composition of GLP-1 and GIP Receptor Dual Agonist and Use Thereof | GLP1R, GIPR, GCGR | MAPT 3236/4885MEN1 2691/4885KMT2A 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.